--- title: "Biofrontera (BFRI) stock listing, news and investor profile" url: "https://aibio.space/companies/biofrontera-bfri/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Biofrontera Inc. (NASDAQ: BFRI), United States. The directory classifies it as Pharmaceuticals: Major." --- BFRI Biofrontera Inc. NASDAQ · United States # Biofrontera (BFRI) news Company Updates · 2026-09-14 ## [Biofrontera gets FDA approval for Ameluz in superficial basal cell carcinoma](https://aibio.space/news/biofrontera-gets-fda-approval-ameluz-superficial-basal-cell-carcinoma/) The company says Ameluz with the RhodoLED lamp is the first and only photodynamic therapy approved in the United States to treat a skin cancer. It plans a launch from late fourth quarter 2026 through first quarter 2027. ## Latest Biofrontera news 1. 2026-08-13 Company Updates [Biofrontera reports second-quarter 2026 net product revenue of $12.0 million](https://aibio.space/news/biofrontera-reports-second-quarter-2026-net-product-revenue-12-0/) Net product revenue rose 32.9% from a year earlier, and gross margin reached 80%. The net loss was $0.6 million, compared with $5.3 million in the prior-year quarter. 2. 2026-05-14 Company Updates [Biofrontera reports first-quarter 2026 results and regains Nasdaq bid price compliance](https://aibio.space/news/biofrontera-reports-first-quarter-2026-results-regains-nasdaq-bid/) Revenue rose about 17% to $10.1 million in the first quarter. Nasdaq confirmed on May 6, 2026 that the company had regained compliance with its minimum bid price requirement. 3. 2025-11-07 Mergers [Biofrontera sells Xepi cream assets to Pelthos Therapeutics, gets $3 million at closing](https://aibio.space/news/biofrontera-sells-xepi-cream-assets-pelthos-therapeutics-gets-3/) Only $3,000,000 was paid at closing on November 6, 2025. The rest of the $10,000,000 maximum depends on a $1,000,000 payment and up to $6 million in sales milestones, and Xepi had no sales in 2024. 4. 2025-10-24 Mergers [Biofrontera Inc. closes purchase of U.S. Ameluz and RhodoLED rights, sells $2.5 million preferred](https://aibio.space/news/biofrontera-inc-closes-purchase-u-s-ameluz-rhodoled-rights-sells-2-5/) Biofrontera Inc. closed its purchase of U.S. rights to Ameluz and RhodoLED from its former parent on October 24, 2025, paying an earnout of 12% or 15% of Ameluz revenue. The same day it closed a $2.5 million second tranche of Series C preferred, and the company says that closing and the deal together keep it above Nasdaq's equity requirement. 5. 2025-06-30 Financings [Biofrontera agrees $11.0 million preferred stock sale to fund U.S. Ameluz rights deal](https://aibio.space/news/biofrontera-agrees-11-0-million-preferred-stock-sale-fund-u-s-ameluz/) The company will sell up to 11,000 Series C preferred shares to fund the purchase of U.S. rights to Ameluz from its former parent. Its royalty falls to 12% or 15% of U.S. sales, while the parent takes a 10% post-money stake. 6. 2025-05-23 Listings [Biofrontera falls below Nasdaq $2,500,000 stockholders' equity requirement](https://aibio.space/news/biofrontera-falls-below-nasdaq-2-500-000-stockholders-equity/) Biofrontera reported stockholders' equity of $469,000 at March 31, 2025, far below the $2,500,000 Nasdaq requires. It has 45 calendar days to submit a plan to regain compliance. ## Biofrontera at a glance - **Ticker**: BFRI - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $4.7 million ### Related companies - [KALA BIO](https://aibio.space/companies/kala-bio/) NASDAQ: KALA - [Vicapsys Life Sciences](https://aibio.space/companies/vicapsys-life-sciences/) OTC: VICP - [SIGA Technologies](https://aibio.space/companies/siga-technologies/) NASDAQ: SIGA - [Evelo Biosciences](https://aibio.space/companies/evelo-biosciences/) OTC: EVLO - [Lisata Therapeutics](https://aibio.space/companies/lisata-therapeutics/) NASDAQ: LSTA - [Ocugen](https://aibio.space/companies/ocugen/) NASDAQ: OCGN - [TherapeuticsMD](https://aibio.space/companies/therapeuticsmd/) NASDAQ: TXMD - [EOM Pharmaceutical Holdings](https://aibio.space/companies/eom-pharmaceutical/) OTC: IMUC ### Also on NASDAQ - [RadNet](https://aibio.space/companies/radnet/) RDNT - [IRIDEX CORP](https://aibio.space/companies/iridex/) IRIX - [Verrica Pharmaceuticals](https://aibio.space/companies/verrica-pharmaceuticals/) VRCA - [Fate Therapeutics](https://aibio.space/companies/fate-therapeutics/) FATE - [Cogent Biosciences](https://aibio.space/companies/cogent-biosciences/) COGT - [ICU MEDICAL INC/DE](https://aibio.space/companies/icu-medical-de/) ICUI ## Biofrontera annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$41.7 million](https://www.sec.gov/Archives/edgar/data/1858685/000149315226011625/) | [$37.3 million](https://www.sec.gov/Archives/edgar/data/1858685/000149315226011625/) | | Research and development | [$3.7 million](https://www.sec.gov/Archives/edgar/data/1858685/000149315226011625/) | [$2.1 million](https://www.sec.gov/Archives/edgar/data/1858685/000149315226011625/) | | Net income (loss) | [-$10.5 million](https://www.sec.gov/Archives/edgar/data/1858685/000149315226011625/) | [-$17.8 million](https://www.sec.gov/Archives/edgar/data/1858685/000149315226011625/) | | Cash from operations | [-$13.4 million](https://www.sec.gov/Archives/edgar/data/1858685/000149315226011625/) | [-$10.3 million](https://www.sec.gov/Archives/edgar/data/1858685/000149315226011625/) | | Cash and equivalents | [$6.4 million](https://www.sec.gov/Archives/edgar/data/1858685/000149315226037834/) | [$5.9 million](https://www.sec.gov/Archives/edgar/data/1858685/000149315226011625/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $4.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Biofrontera What is the ticker symbol of Biofrontera? Biofrontera Inc. trades under the ticker BFRI on NASDAQ. Where is Biofrontera listed? Biofrontera Inc. is listed on NASDAQ. What is the SEC CIK of Biofrontera? The SEC Central Index Key (CIK) for Biofrontera Inc. is 1858685. Its filings are on SEC EDGAR. How many shares does Biofrontera have outstanding? 14,852,359 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Biofrontera listed under? Our directory records Biofrontera Inc. under United States. What does Biofrontera do? Our directory classifies Biofrontera Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Biofrontera? The ISIN recorded for Biofrontera Inc. is US09077D2099. Does aibio.space cover Biofrontera? aibio.space lists Biofrontera Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Biofrontera incorporated? SEC records list its state or country of incorporation as DE. What was Biofrontera's revenue last year? $41.7 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Biofrontera profitable? Biofrontera Inc. reported a net loss of $10.5 million for the fiscal year ended Dec 31, 2025, and used $13.4 million of cash in operations, per its annual report to the SEC. How much does Biofrontera spend on research and development? $3.7 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Biofrontera have? $4.7 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Biofrontera (BFRI) stock news? Our latest story on Biofrontera, dated Sep 14, 2026: "Biofrontera gets FDA approval for Ameluz in superficial basal cell carcinoma". The company says Ameluz with the RhodoLED lamp is the first and only photodynamic therapy approved in the United States to treat a skin cancer. It plans a launch from late fourth quarter 2026 through first quarter 2027. [Source](https://aibio.space/news/biofrontera-gets-fda-approval-ameluz-superficial-basal-cell-carcinoma/). What is Biofrontera's latest stock offering or financing news? Our latest financing story, dated Jun 30, 2025: "Biofrontera agrees $11.0 million preferred stock sale to fund U.S. Ameluz rights deal". The company will sell up to 11,000 Series C preferred shares to fund the purchase of U.S. rights to Ameluz from its former parent. Its royalty falls to 12% or 15% of U.S. sales, while the parent takes a 10% post-money stake. [Source](https://aibio.space/news/biofrontera-agrees-11-0-million-preferred-stock-sale-fund-u-s-ameluz/). ## Investor discussion: Biofrontera Members talk about Biofrontera (BFRI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Biofrontera, newest first. Each line links the filing it comes from. 1. 2026-01-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1858685/000149315226000823/form8-k.htm) 2. 2025-11-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1858685/000149315225021525/form8-k.htm) 3. 2025-11-07 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1858685/000149315225021189/ex99-1.htm) 4. 2025-10-24 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1858685/000149315225019370/form8-k.htm) 5. 2025-09-19 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1858685/000149315225014281/form8-k.htm) 6. 2025-08-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1858685/000164117225023486/form10-q.htm) 7. 2025-08-05 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1858685/000164117225022261/formdef14a.htm) 8. 2025-07-25 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1858685/000164117225021034/formpre14a.htm) 9. 2025-06-30 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1858685/000164117225017052/ex99-1.htm) 10. 2025-06-18 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1858685/000164117225015584/form8-k.htm) 11. 2025-05-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1858685/000164117225012285/form8-k.htm) 12. 2025-05-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1858685/000164117225010330/form8-k.htm) 13. 2025-04-18 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1858685/000164117225005428/form8-k.htm) 14. 2025-01-17 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1858685/000149315225002844/forms-1.htm) 15. 2024-11-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,2.03,3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1858685/000149315224047928/form8-k.htm) 16. 2024-11-22 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1858685/000149315224047306/ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BFRI on TradingView](https://www.tradingview.com/symbols/NASDAQ-BFRI/). ## SEC filings and registration - **SEC name**: Biofrontera Inc. - **CIK**: 1858685 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: BFRI (Nasdaq), BFRIW (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 120 PRESIDENTIAL WAY,, WOBURN, MA, 01801 - **Phone**: 781-245-1325 - **Shares outstanding**: 14,852,359 as of 2026-08-11 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1858685/000149315226042508/form8-k.htm) filed 2026-09-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1858685/000149315226037834/form10-q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1858685/000149315226037610/form8-k.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1858685/000149315226029079/form8-k.htm) filed 2026-06-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1858685/000149315226023119/form10-q.htm) filed 2026-05-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/form8-k.htm) filed 2026-05-14 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1858685/000149315226020616/formdef14a.htm) filed 2026-04-30 - [10-K](https://www.sec.gov/Archives/edgar/data/1858685/000149315226011625/form10-k.htm) filed 2026-03-19 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001858685), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Biofrontera Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BFRI, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Biofrontera Inc. - **Ticker**: BFRI - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US09077D2099 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-BFRI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/biofrontera-bfri/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Biofrontera (BFRI) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/biofrontera-bfri/